Search CORE

6 research outputs found

Autismo: tratamentos psicofarmacológicos e áreas de interesse para desenvolvimentos futuros

Psychiatric Comorbidity Differences in Clinic-Referred Children and Adolescents With ADHD According to the Subtypes and Gender

Author: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.
Ahmad Ghanizadeh
American Psychiatric Association.
Ghanizadeh A.
Hebrani P.
Hechtman L.
Publication venue: 'SAGE Publications'
Publication date
Field of study

Ready for the Challenge of Depression Care in the Medical Home

Author: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder
Elena Smith
Jane Garbutt
Karen Ruecker
Katie Plax
Randall Sterkel
Sherry Dodd
Publication venue: 'SAGE Publications'
Publication date
Field of study

A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)

Author: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder
American Psychiatric Association
Berger I
Biederman J
Faraone SV
Faraone SV
Modesto-Lowe V
Rader R
Shier AC
Spencer TJ
Waxmonsky JG
Wernicke JF
Wilens TE
Publication venue: 'SAGE Publications'
Publication date
Field of study

Effectiveness and Tolerability of Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder

Author: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.
British Medical Association the Royal Pharmaceutical Society of Great Britain &amp
Brown R.T.
Clinical practice guideline: diagnosis and evaluation of the child with attention–deficit/hyperactivity disorder.
Feldman H.
Jensen P.
Schachter H.M.
Taylor E.
Publication venue: 'SAGE Publications'
Publication date
Field of study

Faster Access to Drugs for Serious or Life-Threatening Illnesses Through use of the Accelerated Approval Regulation in the United States

Author: Abbott Biaxin for MAC recommended for accelerated approval as lead agent in combination therapy by FDA Antiviral Drugs Advisory Committee May 10.
Abbott Biaxin for MAC therapy has $1 800 annual cost.
Administration FoodDrug
Administration FoodDrug
Agouron Viracept to be compared to Norvir in clinical endpoint study.
DA Kessler
DA Kessler
Glaxo Wellcome Epivir AIDS therapy review complete in four-and-a-half month accelerated approval process
Milestones in Betaseron approval process.
PharmaciaUpjohn Camptosar for colorectal cancer to be available within six weeks
PharmaciaUpjohn Rescriptor 15.1% rebate available to AIDS Drug Assistance Programs
Pharmacia’s Zinecard full approval depends on Phase IV breast cancer study
President Bill Clinton Vice President Al Gore.
Pulmozyme development may be prototype for other biotech products
R Klein
Rhone-Poulenc Rorer Taxotere lower doses examined in ongoing studies
Roberts ProAmatine to be introduced in mid-October.
Roche Invirase/Hivid combination reduces mortality risk by 68%.
RPR Taxotere June launch likely following accelerated approval May 14
Sequus Doxil for AIDS-related Kaposi’s sarcoma gains accelerated approval Nov. 17
Serono Serostim hGH approved Aug.
SR Shulman
US Bioscience Ethyol to be marketed in US by Alza via $35 mil deal.
Zeneca Casodex for advanced prostate cancer receives accelerated approval from FDA
Publication venue: 'SAGE Publications'
Publication date
Field of study

core

core